FDA Accepts NDA for DHE STS101 Nasal Powder Product for Acute Migraine

The FDA accepted Satsuma Pharmaceuticals 505(b)(2) New Drug Application (NDA) for its investigational new dihydroergotamine (DHE) nasal powder product, STS101, for the acute treatment of migraine. The agency is expected to make a decision on the therapy by January 2024.1 “We are proud to announce the FDA acceptance for review of our NDA STS101, as … Read more